# Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis

> **NCT01039597** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ore Pharmaceuticals, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Mild to Moderate Ulcerative Colitis

## Interventions

- **DRUG:** ORE1001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01039597
- **Lead sponsor:** Ore Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-12
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01039597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01039597, "Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01039597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*